Condition: HPV Infections · Cervical Cancer Stage IIa · Vaginal Cancer · Sponsor: Shanghai Bovax Biotechnology Co., Ltd.
This phase 3 study will evaluate the immunogenicity and safety of Quadrivalent HPV recombinant vaccine in Chinese females aged 9 to 26 years
This description comes directly from the study's public registry record.
Ting Huang · 86-13330993324 · cocoht@163.com
Ji Zhang · 86-(028)85586087 · 20079460@qq.com
Always discuss trial participation with your own doctor first.
| Center for Disease Control and Prevention | Mianyang, Sichuan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05027776